Infant Safety After In-Utero Exposure to Dapivirine Ring or Oral PrEP: 12‑Month Findings from MTN‑042/DELIVER
In a randomized phase 3b trial of pregnant women using the dapivirine vaginal ring or daily oral TDF/FTC for HIV prevention, 12‑month infant follow‑up showed no product‑related serious or grade 3+ adverse events and no HIV transmissions, supporting PrEP use in pregnancy.
